Laboratory tests during direct oral anticoagulant treatment? No

Internal and Emergency Medicine

Volumn 8, Issue 5, 2013, Pages 367-370

  Di Minno, Giovanni ^a   Ricciardi, Elena ^a   Scalera, Antonella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

BLOOD CLOTTING; BLOOD CLOTTING TEST; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG EFFECT; DRUG MONITORING; EDITORIAL; HUMAN; METHODOLOGY; ORAL DRUG ADMINISTRATION; UTILIZATION REVIEW;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS;

EID: 84880511200     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0948-4     Document Type: Editorial

References (20)

1. Coccheri S, Orlando D (2013) New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures. Intern Emerg Med 8: 115-122.
2. Ten Cate H (2012) Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 107: 803-805.
3. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al (2012) Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY Randomized Trial. Circulation 126: 343-348.
4. Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. New Engl J Med 368(14): 1272-1274.
5. Tripodi A (2013) The laboratory and the new oral anticoagulants. Clin Chem 59: 2353-2362.
6. Rohde G (2008) Determination of rivaroxaban-a novel, oral, direct factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 872: 43-50.
7. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, Reeves RA, Lacreta F (2013) Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75: 476-487.
8. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL (2011) Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 9: 133-139.
9. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107: 985-997.
10. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105: 371-378.
11. Harenberg J, Marx S, Weiss C, Kramer R, Samama M, Schulman S (2012) Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 10: 1433-1436.
12. Garcia D, Barrett YC, Ramacciotti E, Weitz JI (2013) Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 11: 245-252.
13. Helin TA, Pakkanen A, Lassila R, Joutsi-Korhonen L (2013) Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories. Clin Chem (in press).
14. Samama MM, Céline G, Le Flem L (2012) Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res 130: S88-S89.
15. Lee S, Mullin R, Blazawski J, Coleman CI (2012) Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS One 7(10): e47473.
16. Pletscher M, Plessow R, Eichler K, Wieser S (2013) Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Med Wkly 143: w13732.
17. Di Minno MN, Russolillo A, Camera M, Parolari A, Tremoli E (2013) Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opin Emerg Drugs 18(1): 9-23.
18. Liesenfeld KH, Lehr T, Dansirikul C et al (2011) Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9: 2168-2175.
19. Mannucci PM (2013) Between scylla and charybdis: thromboprophylaxis in the oldest old with atrial fibrillation. Eur J Int Med (in press).
20. Di Minno G, Russolillo A, Gambacorta C, Prisco D (2013) Improving the use of direct oral anticoagulants in atrial fibrillation. Eur J Int Med (in press).